月別アーカイブ: 2026年4月

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Long-acting Inhaled Medicines (LAIM) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Long-acting Inhaled Medicines (LAIM) market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Respiratory patients (COPD, asthma) require daily maintenance therapy – but frequent dosing reduces adherence and clinical outcomes. Long-acting inhaled medicines (LAIM) solve this with once or twice daily administration through molecular engineering (LABA, LAMA), controlled-release formulations, and advanced particle design. Key drivers include adherence improvement, fixed-dose combinations, and generic LAMA/LABA entry.

The global market for Long-acting Inhaled Medicines (LAIM) was estimated to be worth US$ 2,812 million in 2025 and is projected to reach US$ 3,706 million, growing at a CAGR of 4.1% from 2026 to 2032. In 2024, the average price was approximately US$ 12.68 per unit, with total sales reaching around 213 million units.

Long-acting inhaled medicines (LAIM) achieve prolonged therapeutic effects through molecular engineering and advanced pharmaceutical technologies, reducing dosing frequency and improving patient adherence. Typical LAIM include long-acting beta-agonists (LABA) and long-acting muscarinic antagonists (LAMA), often requiring only once or twice daily administration. Additionally, pharmaceutical strategies such as controlled-release formulations, mucoadhesive systems, and large porous particle designs are employed to extend the pharmacological effect post-inhalation, providing sustained treatment benefits.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098557/long-acting-inhaled-medicines–laim

Market Segmentation & Key Players

The Long-acting Inhaled Medicines (LAIM) market is segmented as below:

Leading Suppliers: Boehringer Ingelheim, Teva Pharmaceutical, Novartis, The Menarini Group, Covis Pharma, Zentiva, Alfasigma, Gebro-Pharma, Kohl Medical, Cipla, GSK, Viatris, LEK-AM, AstraZeneca, Chiesi Farmaceutici, Orion Corporation, Polpharma, Adamed Group, STADA Arzneimittel, Zhejiang Xianjun Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group, Nanchang Helioeast Technology.

Segment by Type: Long-acting Muscarinic Antagonists (LAMAs) | Long-acting Beta-Agonists (LABAs)

Segment by Application: Asthma | COPD | Others

Exclusive Industry Insights

Advanced inhalation formulation technologies: LAIM employ multiple strategies for prolonged action:

• Molecular engineering: Extended half-life (e.g., indacaterol 24h, tiotropium 24h+).
• Controlled-release particles: Large porous particles (>5μm) for sustained deposition.
• Mucoadhesive systems: Prolonged residence time in airways.

Technical differentiation – LAIM classes:

Recent 6-month data (Oct 2025 – Mar 2026):

• COPD largest application (68% revenue), asthma 28%.
• LAMA + LABA fixed-dose combinations fastest-growing (CAGR 5.5%), now 48% of LAIM prescriptions.
• Generic LAIM share reached 35% in Europe, 25% in US.

User case – European health system (UK, 1.5 million respiratory patients): Shifting from twice-daily to once-daily LAIM formulations improved adherence from 58% to 71% over 12 months. Exacerbation rates decreased 14%, saving US$ 38M annually in hospitalization costs.

Adherence impact of once-daily vs. twice-daily:

Application insights: COPD (68%) – LAMA first-line, LABA/LAMA combinations for moderate-severe. Asthma (28%) – LABA as add-on to ICS (step 3–5). Others (4%) – off-label, pediatric, rare diseases.

Emerging LAIM technologies:

• Dry powder formulations: Carrier-based (lactose) or carrier-free (spray-dried).
• Soft mist inhalers: Respimat platform for slow-moving aerosol.
• Nano-carriers: Liposomes, PLGA particles for sustained release (preclinical).

Regional snapshot: North America leads with 46% revenue share (higher branded prices). Europe holds 28% (strong generic penetration). Asia-Pacific fastest-growing (CAGR 5.2%), driven by COPD diagnosis.

Conclusion

The long-acting inhaled medicines market is mature but growing, driven by once-daily convenience, fixed-dose combinations, and generic entry. Success depends on novel particle engineering, device usability, and combination product development. The projected US$ 3.71 billion market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Enteric Premixed Film Coating Powder – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Enteric Premixed Film Coating Powder market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Acid-labile drugs degrade in gastric fluid, causing reduced efficacy or gastric irritation – but uncoated tablets lack protection. Enteric premixed film coating powder solves this with pH-sensitive polymers (dissolving at pH 5.5–7.0) that protect drugs in the stomach and enable targeted intestinal release. Key drivers include generic enteric formulations, traditional Chinese medicine modernization, and bioavailability improvement.

The global market for Enteric Premixed Film Coating Powder was estimated to be worth US$ 79 million in 2025 and is projected to reach US$ 119 million, growing at a CAGR of 6.1% from 2026 to 2032. In 2024, global production reached approximately 2,830 tons, with an average price of US$ 26,500 per ton.

Enteric premixed film coating powder is a composite powder or pre-blended mixture specifically designed for enteric coating of tablets or granules. It is mainly composed of enteric polymers, excipients, plasticizers, and functional additives. Its primary function is to protect the drug from degradation in the stomach and enable release at specific sites in the intestine, thereby improving drug stability and targeted efficacy. The powder can be directly used in coating or spraying processes and is a commonly used excipient in enteric oral solid dosage forms.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098449/enteric-premixed-film-coating-powder

Market Segmentation & Key Players

The Enteric Premixed Film Coating Powder market is segmented as below:

Leading Suppliers: Colorcon, Kerry, Alsiano, Seppic, Imerys, Tianjing ILE, Yuekang Pharmaceutical Group, Lianyungang Wantai Pharm Excipients Tech, Lianyungang Huanyu Bitumen, Shanghai Inno-polymer Pharmaceutical Technology, Lianyungang Hengyang Pharmaceutical.

Segment by Type: Standard Enteric Type | Controlled-Release Enteric Type | Targeted Enteric Type

Segment by Application: Western Medicine | Traditional Chinese Medicine

Exclusive Industry Insights

Discrete spray-dried powder manufacturing: Enteric premix powders are manufactured via spray drying or dry blending – enteric polymers (methacrylic acid copolymers, HPMCAS, shellac) combined with plasticizers (triethyl citrate, PEG), anti-tack agents (talc, glyceryl monostearate), and pigments. Particle size optimized for aqueous film coating (D90 <50μm).

Technical differentiation – coating types:

• Standard Enteric Type (55% revenue): pH 5.5–6.0 dissolution (upper intestine). For acid-labile drugs, NSAID irritation protection. Largest segment.
• Controlled-Release Enteric Type (30% revenue): Combined enteric + sustained-release. For once-daily formulations, colonic delivery. Fastest-growing (CAGR 7.2%).
• Targeted Enteric Type (15% revenue): pH 6.5–7.0 dissolution (lower intestine/colon). For IBD drugs, peptide delivery. Highest value, specialized applications.

Recent 6-month data (Oct 2025 – Mar 2026):

• Western medicine dominates (72% revenue), including PPIs, NSAIDs, mesalamine.
• Traditional Chinese medicine fastest-growing (CAGR 7.5%), with modernization of herbal tablets.
• Aqueous enteric coating (water-based) now 85% of applications (vs. solvent-based 15%).

User case – Generic PPI manufacturer (India, 5 billion tablets/year): Using standard enteric premix powder (pH 6.0 dissolution) for omeprazole delayed-release tablets achieved bioequivalence to branded product. Coating process: 35–40°C inlet temperature, 15–20% weight gain. Batch-to-batch uniformity improved with pre-blended system.

Application insights: Western Medicine (72%) – PPIs (omeprazole, lansoprazole), NSAIDs (aspirin, ibuprofen), mesalamine (UC), pancreatic enzymes. Traditional Chinese Medicine (28%) – enteric-coated herbal tablets, protecting active compounds from gastric degradation.

Key enteric polymers:

Regional snapshot: Asia-Pacific leads with 52% revenue share (China 38%, India 12%), driven by generic and TCM manufacturing. North America holds 22%, Europe 18%.

Conclusion

The enteric premixed film coating powder market grows steadily, driven by generic enteric formulations, TCM modernization, and targeted delivery demands. Success depends on polymer selection, batch consistency, and aqueous coating compatibility. The projected US$ 119 million market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Medicinal Stevioside – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Medicinal Stevioside market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Diabetes, obesity, and hypertension patients require sugar alternatives with therapeutic benefits – but artificial sweeteners have safety concerns, while natural sugars add calories. Medicinal stevioside solves this as a natural, non-caloric high-intensity sweetener (200–300x sucrose) with demonstrated pharmacological activities including glucose regulation, antihypertensive effects, and anti-inflammatory properties. Key drivers include clean-label trends, metabolic disease prevalence, and functional food demand.

The global market for Medicinal Stevioside was estimated to be worth US$ 95 million in 2025 and is projected to reach US$ 143 million, growing at a CAGR of 6.1% from 2026 to 2032. In 2024, global sales reached approximately 2,140 tons, with an average price of US$ 41,500 per ton.

Medicinal stevioside refers to a group of natural high-intensity sweeteners extracted from the leaves of Stevia rebaudiana Bertoni, primarily composed of diterpene glycosides such as stevioside and rebaudiosides. Beyond its wide application as a non-caloric sweetener in the food industry, medicinal stevioside has demonstrated various pharmacological activities, including glucose regulation, antihypertensive effects, anti-inflammatory, and antioxidant properties. These characteristics suggest its potential therapeutic applications in managing conditions such as diabetes, obesity, and cardiovascular disorders.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098444/medicinal-stevioside

Market Segmentation & Key Players

The Medicinal Stevioside market is segmented as below:

Leading Suppliers: PureCircle, Cargill, Sunrise Nutrachem Group, Crodarom, Merisant, Shandong Huaxian Haosen Biotechnology, Shandong Sugar Baby Biotechnolog, Jilin Aodong Biotechnology, Shandong Jiake Biotechnology, Shandong Haigen Biotechnology, Hunan Erkang Pharmaceutical, Sichuan Bolley Heng Pharmaceutical, BONTAC Biotechnology.

Segment by Type: Purity 95%–98% | Purity 98%–99% | Purity Above 99%

Segment by Application: Pharmaceuticals | Health Supplements | Others

Exclusive Industry Insights

Discrete plant extraction & purification: Medicinal stevioside is manufactured via water extraction of Stevia leaves, followed by multi-step purification (membrane filtration, crystallization, chromatography). Higher purity requires additional processing steps (re-crystallization, HPLC polishing), increasing cost exponentially.

Technical differentiation – purity grades:

• Purity 95%–98% (28% revenue): Technical grade for food/beverage applications. Lower cost, contains mixed glycosides (stevioside + rebaudioside A).
• Purity 98%–99% (48% revenue): Pharmaceutical grade. Reduced off-taste (bitter/metallic notes). Largest segment for supplements and pharma excipients.
• Purity Above 99% (24% revenue): High-purity rebaudioside A or stevioside isolates. For research, clinical studies, and premium formulations. Fastest-growing (CAGR 7.2%).

Recent 6-month data (Oct 2025 – Mar 2026):

• Health supplements largest application (52% revenue), driven by sugar-free and keto products.
• Pharmaceuticals fastest-growing (CAGR 6.8%), with clinical trials for diabetes and hypertension.
• Average price increased 5% due to Stevia leaf supply constraints.

User case – Nutraceutical manufacturer (US, stevia-based supplements): Launching stevioside capsules (250mg, 98% purity) for blood sugar support achieved US$ 15M revenue in first year. Key claim: “supports healthy glucose metabolism.” Repeat purchase rate: 34% (vs. industry avg 22%).

Pharmacological evidence (clinical studies):

Application insights: Health Supplements (52%) – capsules, powders, gummies for blood sugar support, weight management. Pharmaceuticals (35%) – API for anti-diabetic formulations, excipient in oral liquids. Others (13%) – functional foods, medical nutrition, research reagents.

Regulatory status:

• FDA: GRAS for food; no approved therapeutic claims (sold as dietary supplement).
• EMA: Novel food approval; pharmaceutical use under investigation.
• China (NMPA): Listed as food additive and API for traditional medicine.

Regional snapshot: Asia-Pacific leads with 55% revenue share (China 40%, Stevia cultivation + processing). North America holds 25% (supplement demand). South America 12% (Paraguay/Brazil origin). Europe 8%.

Conclusion

The medicinal stevioside market is growing rapidly, driven by metabolic disease prevalence, clean-label demand, and functional health trends. Success depends on purity control, taste improvement (rebaudioside M/A), and clinical evidence generation. The projected US$ 143 million market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Ronidazole – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Ronidazole market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Avian and companion animal protozoal infections (Trichomonas, Histomonas, Giardia) cause significant morbidity and economic loss – but treatment options are limited due to resistance and safety concerns. Ronidazole solves this as a nitroimidazole antimicrobial with potent antiprotozoal activity, used in poultry, pigeons, and companion animals. Key challenges include potential neurotoxicity, strict dosing requirements, and regulatory restrictions in food-producing animals.

The global market for Ronidazole was estimated to be worth US$ 18.99 million in 2025 and is projected to reach US$ 25.08 million, growing at a CAGR of 4.1% from 2026 to 2032. In 2024, global production reached approximately 652,140 units, with an average selling price of US$ 29.1 per unit.

Ronidazole is a nitroimidazole-class antimicrobial and antiprotozoal agent used primarily in veterinary medicine to treat infections caused by anaerobic bacteria and certain protozoa, such as Trichomonas and Histomonas species. It functions by penetrating microbial cells and disrupting DNA synthesis through reduction of its nitro group, leading to cell death. Ronidazole is commonly used in birds (especially poultry and pigeons) and companion animals like dogs and cats for conditions such as histomoniasis (blackhead disease) and giardiasis. Due to its potential toxicity and possible carcinogenicity, it is not approved for use in food-producing animals in many countries and is handled with caution. The compound is typically administered orally and requires strict dosage control to minimize side effects, including neurological toxicity.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098356/ronidazole

Market Segmentation & Key Players

The Ronidazole market is segmented as below:

Leading Suppliers: Glentham Life Sciences, Cayman Chemical, Fengchen Group, Nordic Biosite, Manus Aktteva Biopharma LLP, Simson Pharma Limited, Menadiona.

Segment by Type: Powder | Solution | Tablet

Segment by Application: Poultry Farming | Racing Pigeons and Ornamental Birds | Other

Exclusive Industry Insights

Discrete API synthesis: Ronidazole is manufactured via nitroimidazole chemical synthesis, requiring strict quality control for purity (>98%) and residual solvents. API is then formulated into powder (for mixing with feed/water), solution (oral suspension), or tablets (individual dosing).

Technical differentiation – formulation types:

• Powder (48% revenue): Bulk form for mixing into feed or drinking water. Preferred for poultry farming (mass medication). Largest segment.
• Solution (32% revenue): Ready-to-use oral suspension. For pigeons, ornamental birds, and small companion animals.
• Tablet (20% revenue): Individual dosing for dogs, cats, and birds. Highest value per unit, fastest-growing (CAGR 5.2%).

Recent 6-month data (Oct 2025 – Mar 2026):

• Poultry farming largest application (52% revenue), despite regulatory restrictions in many countries (US, EU banned for food animals).
• Racing pigeons segment fastest-growing (CAGR 5.5%), driven by trichomoniasis prevention in competitive birds.
• Average price increased 6% due to raw material cost inflation.

User case – Racing pigeon breeder (Belgium, 500 birds/year): Using ronidazole solution (50mg/kg) for 5-day course to treat trichomoniasis reduced flock infection rate from 35% to 8% during racing season. Treatment cost: US$ 2.50 per bird; prevented loss of racing performance valued at US$ 500+ per bird.

Application insights: Poultry Farming (52%) – histomoniasis (blackhead disease) in turkeys and chickens, trichomoniasis in breeding flocks. Racing Pigeons & Ornamental Birds (35%) – canker (trichomoniasis), routine prevention during racing season. Other (13%) – companion animals (dogs: giardiasis, cats: Tritrichomonas foetus), exotic birds.

Safety considerations:

• Neurotoxicity risk: At high doses (>/= 100mg/kg) or prolonged use, potential for neurological signs (ataxia, seizures).
• Contraindications: Not for use in food-producing animals in US, EU, Canada, Japan.
• Withdrawal periods: Required in countries where approved (typically 14–21 days for meat, 5–7 days for eggs).

Regional snapshot: Europe leads with 42% revenue share (racing pigeon culture). Asia-Pacific holds 32% (poultry production, less restrictive regulations). North America 18% (restricted use in non-food animals only).

Conclusion

The ronidazole market is niche but stable, driven by racing pigeon health, companion animal giardiasis, and poultry histomoniasis treatment where permitted. Success depends on regulatory compliance, dosing precision, and safety monitoring. The projected US$ 25.1 million market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Long-acting Muscarinic Antagonists (LAMAs) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Long-acting Muscarinic Antagonists (LAMAs) market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: COPD patients require sustained bronchodilation to manage symptoms and reduce exacerbations – but short-acting agents provide only 4–6 hour relief. Long-acting muscarinic antagonists (LAMAs) solve this with once-daily dosing (24-hour duration) by blocking M3 receptors in airway smooth muscle. Key drivers include COPD prevalence, GOLD guideline recommendations, and generic LAMA availability.

The global market for Long-acting Muscarinic Antagonists (LAMAs) was estimated to be worth US$ 2,115 million in 2025 and is projected to reach US$ 2,765 million, growing at a CAGR of 4.0% from 2026 to 2032. In 2024, the average price was approximately US$ 11.67 per unit, with total sales volume of around 175 million units.

Long-acting muscarinic antagonists (LAMAs) are a class of bronchodilators widely used in the management of chronic obstructive pulmonary disease (COPD). They work by blocking M3 muscarinic receptors in the airway smooth muscles, providing sustained bronchodilation. Compared with short-acting agents, LAMAs have a prolonged duration of action, typically lasting for 24 hours, which allows once-daily dosing and improves lung function as well as patients’ quality of life. Representative drugs include tiotropium, usually administered through dry powder inhalers or nebulizers.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098353/long-acting-muscarinic-antagonists–lamas

Market Segmentation & Key Players

The Long-acting Muscarinic Antagonists (LAMAs) market is segmented as below:

Leading Suppliers: Boehringer Ingelheim, Teva Pharmaceutical, Novartis, The Menarini Group, Covis Pharma, Zentiva, Alfasigma, Gebro-Pharma, Kohl Medical, Cipla, GSK, Zhejiang Xianjun Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group, Nanchang Helioeast Technology.

Segment by Type: Aclidinium | Glycopyrrolate | Tiotropium | Umeclidinium | Others

Segment by Application: Asthma | COPD | Others

Exclusive Industry Insights

Discrete DPI/nebulizer formulation: LAMAs are formulated as micronized API (<5μm) blended with lactose (DPIs) or aqueous solutions (nebulizers). Receptor binding: LAMAs dissociate slowly from M3 receptors, providing prolonged bronchodilation (24+ hours).

Technical differentiation – LAMA molecules:

Recent 6-month data (Oct 2025 – Mar 2026):

• COPD dominates (92% of revenue), with minimal asthma use (step-up therapy).
• Tiotropium largest segment (58% revenue), generic entry in US (2025) accelerating.
• Triple therapy (LAMA + LABA + ICS) fastest-growing (CAGR 6.5%), preferred for frequent exacerbators.

User case – National health service (UK, 1.2 million COPD patients): Formulary preference for generic tiotropium DPI (post-patent) reduced annual LAMA spend by US$ 65M (38% savings). Adherence rates unchanged (72%), exacerbation rates stable over 18 months.

GOLD 2025 guideline recommendations:

Application insights: COPD (92%) – maintenance therapy for moderate-to-very severe COPD (GOLD Groups B/E). Asthma (6%) – add-on therapy for uncontrolled asthma (off-label, step 5). Others (2%) – off-label uses.

Regional snapshot: North America leads with 48% revenue share (higher branded prices). Europe holds 28% (generic penetration accelerating). Asia-Pacific fastest-growing (CAGR 5.2%), driven by COPD diagnosis improvement and aging populations.

Conclusion

The LAMA market is mature but stable, driven by COPD prevalence, generic tiotropium entry, and triple therapy adoption. Success depends on DPI device usability, patent expiration management, and combination product development. The projected US$ 2.77 billion market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Short-acting Bronchodilators – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Short-acting Bronchodilators market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Asthma and COPD patients require rapid relief during acute attacks – but delayed or inadequate rescue medication can lead to severe exacerbations. Short-acting bronchodilators (SABAs/SAMAs) solve this with fast-acting (3–5 minute onset) bronchodilation via metered-dose inhalers, using APIs like albuterol, levalbuterol, and ipratropium. Key drivers include respiratory disease prevalence, emergency preparedness, and generic availability.

The global market for Short-acting Bronchodilators was estimated to be worth US$ 4,489 million in 2025 and is projected to reach US$ 5,932 million, growing at a CAGR of 4.1% from 2026 to 2032. In 2024, the average global price was about US$ 19.6 per unit, with total sales reaching approximately 220 million units.

Short-acting bronchodilators (SABAs and SAMAs) are critical rescue medications used during acute asthma attacks and COPD exacerbations. Their upstream supply chain involves active pharmaceutical ingredients (APIs) such as albuterol, levalbuterol, and ipratropium, propellants like HFA-134a and HFA-227, and delivery components including aluminum canisters, metering valves, and spray actuators. These key materials are mainly provided by specialized global suppliers such as Linde and Chemours (propellants), as well as Aptar and Lindal (aerosol valves and actuator systems). Due to high technical and regulatory barriers, manufacturers rely on a stable and highly compliant international supply chain. On the downstream side, the primary customers include hospitals, clinics, retail pharmacies, and pharmacy chains, with strong demand in both emergency and home-care scenarios. Leading manufacturers such as GSK, AstraZeneca, Boehringer Ingelheim, and Teva dominate the global market, creating a landscape where branded products and generics coexist.

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098340/short-acting-bronchodilators

Market Segmentation & Key Players

The Short-acting Bronchodilators market is segmented as below:

Leading Suppliers: Boehringer Ingelheim, GSK, Teva Pharmaceutical, Prasco Laboratories, Cipla, Lupin Laboratories, Laboratorio Aldo-Union, Polpharma, Jewim Pharmaceutical, Heilongjiang Fulekang Pharmaceutical, Shanghai Pharmaceuticals, Lunan Better Pharmaceutical, China Resources Double Crane Pharmaceutical.

Segment by Type: Albuterol (Salbutamol) | Levalbuterol | Ipratropium | Others

Segment by Application: Asthma | COPD | Others

Exclusive Industry Insights

Discrete pressurized MDI manufacturing: Short-acting bronchodilators are manufactured via pressure-fill process – micronized API suspended in HFA propellant, filled into aluminum canisters with metering valves (50–100μL per actuation). Valve precision critical for dose consistency (±15% per USP).

Technical differentiation – molecule selection:

• Albuterol (68% revenue): Most widely used SABA, 4–6 hour duration, onset 3–5 minutes. Largest segment, multiple generics.
• Levalbuterol (15% revenue): R-isomer of albuterol, fewer cardiac side effects, higher cost. Preferred for sensitive patients.
• Ipratropium (12% revenue): SAMA, slower onset (15 minutes), longer duration (6–8 hours). Often combined with albuterol for COPD.
• Others (5% revenue): Fenoterol, terbutaline (regional markets).

Recent 6-month data (Oct 2025 – Mar 2026):

• Asthma largest application (68% revenue), COPD fastest-growing (CAGR 4.8%).
• Generic albuterol MDIs captured 52% of US market (up from 38% in 2020).
• Propellant transition to low-GWP HFO-1234ze under EU regulation (effective 2026).

User case – Urban health system (US, 1M emergency visits/year): Stocking generic albuterol MDIs in emergency departments and outpatient pharmacies reduced rescue medication cost by 42% (US$ 8.2M annually). Patient outcomes (hospitalization rates, revisit rates) unchanged over 18 months.

Application insights: Asthma (68%) – acute attack relief, exercise-induced bronchospasm prevention. COPD (28%) – acute exacerbation management, adjunct to maintenance therapy. Others (4%) – bronchospasm from other causes.

Key market dynamics:

Regional snapshot: North America leads with 48% revenue share (higher branded prices). Europe holds 24% (strong generic penetration). Asia-Pacific fastest-growing (CAGR 5.8%), driven by asthma/COPD diagnosis improvement.

Conclusion

The short-acting bronchodilator market is mature but growing, driven by generic expansion, respiratory disease prevalence, and emerging market access. Success depends on propellant transition, valve precision, and cost competitiveness. The projected US$ 5.93 billion market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp

Global Leading Market Research Publisher QYResearch announces the release of its latest report “Inhaled Corticosteroids (ICS) Medications – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Inhaled Corticosteroids (ICS) Medications market, including market size, share, demand, industry development status, and forecasts for the next few years.

Addressing core industry needs: Asthma and COPD patients require daily anti-inflammatory therapy to prevent exacerbations – but oral corticosteroids cause systemic side effects. Inhaled corticosteroids (ICS) solve this with targeted airway delivery via dry powder or metered-dose inhalers, minimizing systemic absorption. Key drivers include asthma prevalence, GINA guideline recommendations, and generic ICS availability.

The global market for Inhaled Corticosteroids (ICS) Medications was estimated to be worth US$ 3,512 million in 2025 and is projected to reach US$ 4,474 million, growing at a CAGR of 3.6% from 2026 to 2032. In 2024, the average global price is around US$ 18.7 per unit, with total sales reaching approximately 182 million units.

Inhaled corticosteroids (ICS) are prescription medications that help reduce inflammation in the lungs. They are typically used daily to prevent asthma attacks and are sometimes prescribed for chronic obstructive pulmonary disease (COPD) or other respiratory conditions. ICS medications are commonly delivered via dry powder inhalers, allowing targeted treatment in the airways while minimizing systemic side effects. Examples include Beclomethasone dipropionate (Qvar®), Budesonide (Pulmicort®), Ciclesonide (Alvesco®), Fluticasone (Arnuity®, Flovent®), and Mometasone (Asmanex®).

【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/6098301/inhaled-corticosteroids–ics–medications

Market Segmentation & Key Players

The Inhaled Corticosteroids (ICS) Medications market is segmented as below:

Leading Suppliers: GSK, Chiesi Farmaceutici, Teva Pharmaceutical, Sumitomo Pharma, Cipla, Glenmark Pharmaceuticals, Orion Corporation, Bausch Health, Viatris, Novartis, Covis Pharma, Zentiva, AstraZeneca, Lunan Better Pharmaceutical, Jewim Pharmaceutical, Shanghai Pharmaceuticals, Zhejiang Xianjun Pharmaceutical, Anhui Wellman Pharmaceutical.

Segment by Type: Beclomethasone Dipropionate | Budesonide | Ciclesonide | Fluticasone | Mometasone | Others

Segment by Application: Asthma | COPD | Others

Exclusive Industry Insights

Discrete inhaler manufacturing: ICS medications are formulated as micronized API (<5μm) blended with carrier lactose (for DPIs) or suspended in HFA propellant (for MDIs). Device engineering is critical: consistent dose delivery despite variable patient inhalation flow rates.

Technical differentiation – ICS molecules:

Recent 6-month data (Oct 2025 – Mar 2026):

• Fluticasone largest segment (38% revenue), established market leader.
• Budesonide fastest-growing (CAGR 4.5%) in emerging markets (generic availability).
• Generic ICS share reached 35% in US (up from 22% in 2020).

User case – National health service (UK, 5 million asthma patients): Formulary preference for generic budesonide DPI over branded fluticasone reduced annual ICS spend by US$ 45M (28% savings). Clinical outcomes (exacerbation rates, hospitalizations) unchanged at 24 months.

Application insights: Asthma (78%) – maintenance therapy across all severities (GINA Steps 2-5). COPD (18%) – ICS indicated for eosinophilic phenotype, frequent exacerbators. Others (4%) – allergic rhinitis (nasal sprays), eosinophilic esophagitis.

Guideline-driven prescribing (GINA 2025):

• Step 1: SABA as needed.
• Step 2: Low-dose ICS (plus SABA).
• Step 3: Low-dose ICS/LABA.
• Step 4: Medium-dose ICS/LABA.
• Step 5: High-dose ICS/LABA + add-on therapy.

Regional snapshot: North America leads with 48% revenue share (higher branded drug prices). Europe holds 28% (strong generic penetration). Asia-Pacific fastest-growing (CAGR 4.8%), driven by asthma diagnosis improvement.

Conclusion

The inhaled corticosteroids market is mature but stable, driven by asthma/COPD prevalence and generic expansion. Success depends on device usability, generic competition management, and combination ICS/LABA products. The projected US$ 4.47 billion market by 2032 appears achievable.

Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp